Myriad Genetics, Inc. (MYGN): Among Billionaire Larry Robbins' Stock Picks with Huge Upside Potential

We recently published a list of Billionaire Larry Robbins’ 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Myriad Genetics, Inc. (NASDAQ:MYGN) stands against other stock picks with huge upside potential.

Larry Robbins is an American hedge fund manager and philanthropist who founded Glenview Capital Management in 2000. The firm manages capital for investors across a range of private investment funds. Robbins is currently the CEO of his firm. He graduated with honors from the Jerome Fisher Program in Management and Technology at the University of Pennsylvania in 1992 and earned a BS in economics with concentrations in accounting, finance, and marketing. He also has a BS in engineering with a major in systems engineering. He became a Certified Public Accountant in Illinois in 1991. Before founding Glenview Capital, Robbins worked as a portfolio manager at Omega Advisors, which is a prominent hedge fund founded by Leon Cooperman. In 2017, Larry Robbins also began serving as chairman of the Robin Hood Foundation, which fights poverty in New York City. Through his Family Foundation, he is an active supporter of education reform both in NYC and on the national level. He also serves as Chairman of the Board of KIPP NY and is a Board Member of Zearn and Relay Graduate School of Education.

Due to his sharp analytical skills and a focus on the healthcare sector, Robbins has built a reputation as one of the most influential figures in the hedge fund industry. Glenview Capital Management has 6 clients and discretionary assets under management (AUM) of $5.6 billion as reported in its Form ADV dated 4 March 2025. The last reported 13F filing for Q4 2024 included $3.95 billion in managed 13F securities and a top 10 holdings concentration of 65.22%. Earlier in September 2024, Institutional Investor reported that Glenview Capital Management was on track for its best year in 5 years. The flagship Glenview Capital Partners fund was up 3.45% in August 2024 and 17.2% through the first 8 months of the year. One of the reasons behind this performance is the hedge fund’s diversification away from a historically heavy concentration in healthcare stocks. Glenview Capital Management has now expanded its investments into the tech sector and other industries. Larry Robbins believes in a straightforward investment strategy:

“There are only two things that matter in investing. What are they going to earn, and what multiple are people going to put on that. Let’s not make our business any more complicated than this.”

Our Methodology

To compile the list of billionaire Larry Robbins’ 10 stock picks with huge upside potential, we sifted through Q4 2024 13F filings of Glenview Capital from Insider Monkey. From these filings, we checked the upside potential from CNN for the top 30 stock picks and ranked the stocks in ascending order of this upside potential. We have also added Glenview Capital’s stake in each stock as well as the broader hedge fund sentiment for it.

Note: All data was sourced on May 8.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

Myriad Genetics, Inc. (NASDAQ:MYGN)

Glenview Capital’s Stake: $56.99 million

Number of Hedge Fund Holders: 21

Average Upside Potential as of May 8: 87.35%

Myriad Genetics, Inc. (NASDAQ:MYGN) is a molecular diagnostic testing and precision medicine company. It offers diagnostic tests for oncology, women’s health, and pharmacogenomics. It has a license collaboration with Illumina, Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, the University of Rochester Medical Center, and Flatiron Health.

Myriad Genetics saw 11% revenue growth in 2024, which was partly driven by its Pharmacogenomics business that is centered around the GeneSight test. In 2024, GeneSight revenues saw an increase of 23% year-over-year, and this demand continued into Q4 with a 14% revenue increase. Myriad is expanding access to GeneSight, despite recent reimbursement challenges with UnitedHealthcare.

It’s focusing on digital engagement to increase provider and patient awareness and optimizing patient direct payment options. Myriad Genetics, Inc. (NASDAQ:MYGN) is also encouraged by the momentum of biomarker legislation, which supports access to precision medicine. Furthermore, new clinical data shows that the economic utility of GeneSight is expected to be published in 2025, which could further support its adoption.

Overall, MYGN ranks 2nd on our list of billionaire Larry Robbins’ stock picks with huge upside potential. While we acknowledge the potential of MYGN as an investment, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than MYGN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.